Showing 2211-2220 of 3223 results for "".
- Alnylam and Regeneron to Partner for RNAi Treatmentshttps://modernod.com/news/alnylam-regeneron-to-partner-for-rnai-treatments/2476457/Alnylam Pharmaceuticals and Regeneron Pharmaceuticals have agreed to jointly develop treatments for eye and central nervous system diseases using gene-silencing technology RNA interference (RNAi). Regeneron will make a $400 million upfront payment to Alnylam and also purchase $400 mill
- Alcon Debuts as Independent, Publicly Traded Companyhttps://modernod.com/news/alcon-debuts-as-independent-publicly-traded-company/2476453/After 8 years under Novartis ownership, Alcon is officially an independent, publicly traded company. On Tuesday, Alcon completed its separation from Novartis and its shares begin trading on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” American depositary recei
- Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to Board of Directorshttps://modernod.com/news/allegro-ophthalmics-appoints-marc-carlson-and-rebecca-colbert-to-board-of-directors/2476454/Allegro Ophthalmics announced that two new independent members—Marc Carlson and Rebecca Colbert—have been appointed to the company’s Board of Directors with Ms. Colbert serving as Chairperson of the Board’s Audit Committee. Bringing extensive executive level commercial and financial leadership ex
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- Alcon Announces Timothy Stonesifer as Chief Financial Officerhttps://modernod.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/Alcon announced that Timothy C. Stonesifer will join the company as its new Senior Vice President and Chief Financial Officer, in conjunction with the company’s April 9 spinoff from Novartis. He will report directly to David Endicott, Alcon’s Chief Executive Officer, and bec
- Allergan and Molecular Partners Announce Topline Safety Results From MAPLE Study of Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/2476430/Allergan and Molecular Partners announced topline safety results from MAPLE, a 28-week open-label study which enrolled 123 age-related neovascular macular degeneration (AMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, trea
- Alcon Adds Topical Local Anesthetic Alcaine 0.5% 15mL to its Ophthalmic Portfoliohttps://modernod.com/news/alcon-adds-topical-local-anesthetic-alcaine-0-5-15ml-to-its-ophthalmic-portfolio/2476426/Alcon announced the latest addition of Alcaine (proparacaine hydrochloride ophthalmic solution, USP) 0.5% 15mL to its procedural eye drops portfolio, which is made up of mydriatic, cycloplegic, diagnostic, and anesthetic products. Alcaine 0.5% 15mL, the only branded proparacaine available,
- Alcon Launches Expanded Parameters for Dailies AquaComfort Plus Toric Contact Lenseshttps://modernod.com/news/alcon-launches-expanded-parameters-for-dailies-aquacomfort-plus-toric-contact-lenses/2476425/Alcon has introduced a broader range of parameters for its Dailies AquaComfort Plus Toric contact lenses, giving it the most parameters of any daily disposable contact lens for people with astigmatism, according to a company news release. With this expansion, eye care professionals (ECPs) will ha
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Aldeyra Therapeutics Announces Positive Results From Phase 3 Allergic Conjunctivitis Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-the-phase-3-alleviate-trial-in-patients-with-allergic-conjunctivitis/2476416/Aldeyra Therapeutics announced positive results from the phase 3 ALLEVIATE trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary and the key secondary endpoint for both concentrations of reproxalap. “We a